Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of Health-Related Quality of Life among Patients with Cervical Cancer in Indonesia

  • Endarti, Dwi (Division of Social and Administrative Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University) ;
  • Riewpaiboon, Arthorn (Division of Social and Administrative Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University) ;
  • Thavorncharoensap, Montarat (Division of Social and Administrative Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University) ;
  • Praditsitthikorn, Naiyana (Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health) ;
  • Hutubessy, Raymond (Initiative for Vaccine Research, World Health Organization) ;
  • Kristina, Susi Ari (Faculty of Pharmacy, Gadjah Mada University)
  • Published : 2015.04.29
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Evaluation of health-related quality of life (HRQOL) in cervical cancer patients is important in order to design the interventions for improving patient outcomes. Reports of HRQOL among cervical cancer patients in Indonesia are limited. Moreover, measurement using EQ-5D-3L is to our best knowledge has hitherto not been performed. This study aimed to examine the HRQOL of cervical cancer patients in Indonesia using EQ-5D-3L. Materials and Methods: A cross-sectional study was conducted by interviewing cervical cancer patients using the EQ-5D-3L questionnaire. Percentages of patients who reported having problems in each dimension of EQ-5D as well as EQ-5D index score (utility) were calculated. Results: Our findings indicated that the most frequent reported problems were pain/discomfort (67.8%) followed by anxiety/depression (57.5%). The mean of EQ-5D VAS was 75.8 (SD=17.0). The mean (SD) utility scores were 0.85 (0.19), 0.76 (0.20), 0.71 (0.21), and 0.77 (0.13) for cervical cancer patients in stage I, II, III, and IV, respectively. Conclusions: Cervical cancer significantly affects patient HRQOL. Efforts should be made to improve the quality of life of cervical cancer patients especially in terms of pain /discomfort and anxiety/depression reduction.

Keywords

References

  1. Aaronson NK, Ahmedzai S, Bergman B, et al (1993). The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI, 85, 365-76. https://doi.org/10.1093/jnci/85.5.365
  2. Akkuzu G, Talas MS, Ortac F (2014). Functional status in Turkish women with gynecological cancer. Asian Pac J Cancer Prev, 15, 2045-9. https://doi.org/10.7314/APJCP.2014.15.5.2045
  3. Azmawati MN, Najibah E, Hatta MD, et al (2014). Quality of life by stage of cervical cancer among Malaysian patients. Asian Pac J Cancer Prev, 15, 5283-6. https://doi.org/10.7314/APJCP.2014.15.13.5283
  4. Bailey H, Kind P (2010). Preliminary findings of an investigation into the relationship between national culture and EQ-5D value sets. Qual Life Res, 19, 1145-54. https://doi.org/10.1007/s11136-010-9678-5
  5. Brazier J, Roberts J, Deverill M (2002). The estimation of a preference-based measure of health from the SF-36. J Health Econ, 21, 271-92. https://doi.org/10.1016/S0167-6296(01)00130-8
  6. Cella D, Huang HQ, Monk BJ, et al (2010). Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol, 119, 531-7. https://doi.org/10.1016/j.ygyno.2010.08.020
  7. Devlin NJ, Krabbe PF (2013). The development of new research methods for the valuation of EQ-5D-5L. Eur J Health Econ, 14, 1.
  8. Drummond F, Torrance GW (2005). Methods for the economic evaluation of health care programmes, Oxford University Press.
  9. EuroQol Group (2015). EQ-5D-3L. http://www.euroqol.org/eq-5d-products/eq-5d-3l.html (12th February 2015).
  10. Ezat WS, Noraziani K, Sabrizan O (2012). Improving quality of life among cancer patients in Malaysia. Asian Pac J Cancer Prev, 13, 1069-75. https://doi.org/10.7314/APJCP.2012.13.3.1069
  11. Ferlay J, Soerjomataram I, Ervik M, et al (2012). GLOBOCAN 2012, Cancer incidence and mortality worldwide, Version 1.0, IARC CancerBase No. 11. http://globocan.iarc.fr (24th December 2014).
  12. Galante J, Augustovski F, Colantonio L, et al (2011). Estimation and comparison of EQ-5D health states' utility weights for pneumococcal and human papillomavirus diseases in Argentina, Chile, and the United Kingdom. Value Health, 14, 60-4.
  13. Galloway SK, Baker M, Giglio P, et al (2012). Depression and anxiety symptoms relate to distinct components of pain experience among patients with breast cancer. Pain Res Treat, 2012, 851276.
  14. Gao F, Ng G-Y, Cheung Y-B, et al (2009). The Singaporean English and Chinese versions of the EQ-5D achieved measurement equivalence in cancer patients. J Clin Epidemiol, 62, 206-13. https://doi.org/10.1016/j.jclinepi.2008.03.007
  15. Goker A, Guvenal T, Yanikkerem E, et al (2011). Quality of life in women with gynecologic cancer in Turkey. Asian Pac J Cancer Prev, 12, 3121-8.
  16. Greimel ER, Kuljanic Vlasic K, Waldenstrom AC, et al (2006). The european organization for research and treatment of cancer (EORTC) quality of life questionnaire cervical cancer module. Cancer, 107, 1812-22. https://doi.org/10.1002/cncr.22217
  17. Grzankowski KS, Carney M (2011). Quality of life in ovarian cancer. Cancer Control, 18, 52-8.
  18. Higginson IJ, Carr AJ (2001). Measuring quality of life: Using quality of life measures in the clinical setting. BMJ, 322, 1297-300. https://doi.org/10.1136/bmj.322.7297.1297
  19. Horsman J, Furlong W, Feeny D, et al (2003). The Health Utilities Index (HUI(R)): concepts, measurement properties and applications. Health Qual Life outcomes, 1, 54. https://doi.org/10.1186/1477-7525-1-54
  20. Jhita T, Petrou S, Gumber A, et al (2014). Ethnic differences in health related quality of life for patients with type 2 diabetes. Health Qual Life Outcomes, 12, 83. https://doi.org/10.1186/1477-7525-12-83
  21. Karimi Zarchi M, Behtash N, Chiti Z, et al (2009). Cervical cancer and HPV vaccines in developing countries. Asian Pac J Cancer Prev, 10, 969-74.
  22. Lahana E, Niakas D (2013). Investigating differences in healthrelated quality of life of greeks and albanian immigrants with the generic EQ-5D Questionnaire. BioMed Research International, 2013.
  23. Lang H-C, Chuang L, Shun S-C, et al (2010). Validation of EQ-5D in patients with cervical cancer in Taiwan. Support Care Cancer, 18, 1279-86. https://doi.org/10.1007/s00520-009-0745-9
  24. Lee JA, Kim SY, Kim Y, et al (2014). Comparison of healthrelated quality of life between cancer survivors treated in designated cancer centers and the general public in Korea. Jpn J Clin Oncol, 44, 141-52. https://doi.org/10.1093/jjco/hyt184
  25. Linden W, Vodermaier A, MacKenzie R, et al (2012). Anxiety and depression after cancer diagnosis: Prevalence rates by cancer type, gender, and age. J Affect Disord, 141, 343-51. https://doi.org/10.1016/j.jad.2012.03.025
  26. Longworth L, Yang Y, Young T, et al (2014). Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: systematic review, statistical modelling and survey. Health Technol Assess, 18, 9.
  27. Marcellusi A, Capone A, Favato G, et al (2015). Health utilities lost and risk factors associated with HPV-Induced diseases in men and women: The HPV italian collaborative study group. Clin Ther, 37, 156-67. https://doi.org/10.1016/j.clinthera.2014.11.002
  28. Marcus DA (2011). Epidemiology of cancer pain. Curr Pain Headache Rep, 15, 231-4. https://doi.org/10.1007/s11916-011-0208-0
  29. Matalqah LM, Radaideh KM, Yusoff ZM, et al (2011). Healthrelated quality of life using EQ-5D among breast cancer survivors in comparison with age-matched peers from the general population in the state of Penang, Malaysia. J Public Health, 19, 475-80. https://doi.org/10.1007/s10389-011-0406-6
  30. Md Yusof FA, Goh A, Azmi S (2012). Estimating an EQ-5D value set for Malaysia using time trade-off and visual analogue scale methods. Value Health, 15, 85-90.
  31. Moore MA, Manan A, Chow KY, et al (2010). Cancer epidemiology and control in peninsular and island South-East Asia-past, present and future. Asian Pac J Cancer Prev, 11, 81-98.
  32. Murasawa H, Konno R, Okubo I, et al (2014). Evaluation of health-related quality of life for hypothesized medical states associated with cervical cancer. Asian Pac J Cancer Prev, 15, 9679-85. https://doi.org/10.7314/APJCP.2014.15.22.9679
  33. Nazik E, Ozdemir F, Soydan S (2014). Social support and quality of life in Turkish patients with gynecologic cancer. Asian Pac J Cancer Prev, 15, 3081-6. https://doi.org/10.7314/APJCP.2014.15.7.3081
  34. Norman R, Cronin P, Viney R, et al (2009). International comparisons in valuing EQ 5D health states: A review and analysis. Value Health, 12, 1194-200. https://doi.org/10.1111/j.1524-4733.2009.00581.x
  35. Oemar M, Janssen B (2013). User guide: basic information on how to use EQ-5D-5L instrument. EuroQol Group.
  36. Oemar M, Oppe M (2013). User guide: basic information on how to use EQ-5D-3L instrument. EuroQol Group.
  37. Pearcy R, Waldron D, O'Boyle C, et al (2008). Proxy assessment of quality of life in patients with prostate cancer: how accurate are partners and urologists? J R Soc Med, 101, 133-8. https://doi.org/10.1258/jrsm.2008.081002
  38. Perwitasari DA, Atthobari J, Mustofa M, et al (2012). Impact of chemotherapy-induced nausea and vomiting on quality of life in indonesian patients with gynecologic cancer. Int J of Gynecol Cancer, 22, 139-45. https://doi.org/10.1097/IGC.0b013e318234f9ee
  39. Quinn MA, Benedet JL, Odicino F, et al (2006). Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet, 95, 43-103. https://doi.org/10.1016/S0020-7292(06)60030-1
  40. Rabin R, Charro Fd (2001). EQ-SD: a measure of health status from the EuroQol Group. Ann Med, 33, 337-43. https://doi.org/10.3109/07853890109002087
  41. Reeler A, Qiao Y, Dare L, et al (2009). Women's cancers in developing countries: from research to an integrated health systems approach. Asian Pac J Cancer Prev, 10, 519-26.
  42. Schipper H, Clinch J, McMurray A, et al (1984). Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol, 2, 472-83.
  43. Tan Z, Liang Y, Liu S, et al (2013). Health-related quality of life as measured with EQ-5D among populations with and without specific chronic conditions: a population-based survey in Shaanxi Province, China. PLoS One, 8, 65958. https://doi.org/10.1371/journal.pone.0065958
  44. Teckle P, Peacock S, McTaggart-Cowan H, et al (2011). The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities. Health Qual Life Outcomes, 9, 106. https://doi.org/10.1186/1477-7525-9-106
  45. Traeger L, Greer JA, Fernandez-Robles C, et al (2012). Evidence-based treatment of anxiety in patients with cancer. J Clin Oncol, 30, 1197-205. https://doi.org/10.1200/JCO.2011.39.5632
  46. Wahidin M, Noviani R, Hermawan S, et al (2012). Populationbased cancer registration in Indonesia. Asian Pac J Cancer Prev, 13, 1709-10. https://doi.org/10.7314/APJCP.2012.13.4.1709
  47. Wilson KA, Dowling AJ, Abdolell M, et al (2000). Perception of quality of life by patients, partners and treating physicians. Qual Life Res, 9, 1041-52. https://doi.org/10.1023/A:1016647407161
  48. Zhao ZM, Pan XF, Lv SH, et al (2014). Quality of life in women with cervical precursor lesions and cancer: a prospective, 6-month, hospital-based study in China. Chin J Cancer, 33, 339-45.

Cited by

  1. How is Indonesia coping with its epidemic of chronic noncommunicable diseases? A systematic review with meta-analysis vol.12, pp.6, 2017, https://doi.org/10.1371/journal.pone.0179186
  2. The Indonesian EQ-5D-5L Value Set vol.35, pp.11, 2017, https://doi.org/10.1007/s40273-017-0538-9
  3. When flawed modeling justifies cost-effectiveness: Making sense of “Band-Aid” modeling vol.124, pp.15, 2018, https://doi.org/10.1002/cncr.31545
  4. Reply to When flawed modeling justifies cost-effectiveness: Making sense of “Band-Aid” modeling vol.124, pp.15, 2018, https://doi.org/10.1002/cncr.31544